ストックスクリーナーアプリを入手
37.74
0.34%
-0.13
アフターアワーズ：
37.74
前日終値:
$37.87
開ける：
$37.92
24時間の取引高:
194.46K
Relative Volume:
0.58
時価総額：
$2.08B
収益：
$651.97M
当期純損益:
$59.71M
株価収益率:
35.28
EPS:
1.0696
ネットキャッシュフロー:
$172.03M
1週間 パフォーマンス:
+0.67%
1か月 パフォーマンス:
+4.20%
6か月 パフォーマンス:
+30.36%
1年 パフォーマンス:
+35.22%
1日の値動き範囲:
$37.27
$38.13
1週間の範囲:
$37.08
$38.68
52週間の値動き範囲:
$25.53
$39.37
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
名前
Supernus Pharmaceuticals Inc
セクター
電話
301-838-2500
住所
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
37.74 | 2.08B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-09-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 再開されました | Jefferies | Buy |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-04-13 | アップグレード | Jefferies | Hold → Buy |
| 2020-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 再開されました | Jefferies | Hold |
| 2019-11-08 | ダウングレード | Berenberg | Buy → Hold |
| 2019-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2019-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2018-11-12 | 繰り返されました | B. Riley FBR | Buy |
| 2018-01-18 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | アップグレード | Janney | Neutral → Buy |
| 2017-11-08 | アップグレード | Stifel | Hold → Buy |
| 2017-10-19 | 開始されました | FBR & Co. | Buy |
| 2017-09-19 | ダウングレード | Stifel | Buy → Hold |
| 2017-07-17 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 開始されました | Janney | Neutral |
| 2017-06-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | アップグレード | Jefferies | Hold → Buy |
| 2015-11-05 | 繰り返されました | Northland Capital | Outperform |
| 2015-10-28 | 開始されました | Northland Capital | Outperform |
すべてを表示
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Supernus Pharmaceuticals, Inc. Enters into Lease Agreement for Approximately 136,016 Square Feet for its New Headquarters with Advent Key West, LLC - Marketscreener.com
Hennion & Walsh Asset Management Inc. Acquires 25,004 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Burney Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by JPMorgan Chase & Co. - Defense World
Despite the downward trend in earnings at Supernus Pharmaceuticals (NASDAQ:SUPN) the stock advances 3.1%, bringing five-year gains to 56% - Simply Wall St
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
SUPN (Supernus Pharmaceuticals) Intrinsic Value: DCF (FCF B - GuruFocus.com
(SUPN) Investment Report - Stock Traders Daily
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Cantor Fitzgerald - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Has $8.90 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Franklin Resources Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - Stock Traders Daily
Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Barclays PLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Geode Capital Management LLC Has $46.22 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Grows Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
HighTower Advisors LLC Takes $264,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stifel Financial Corp Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Wellington Management Group LLP - MarketBeat
Fmr LLC Buys 8,499 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Trading Signals - Stock Traders Daily
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewswire
Thinking about buying stock in BigBear.ai, Supernus Pharmaceuticals, Collegium Pharmaceutical, Duolingo, or Cryptoblox Technologies? - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.50 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap UpWhat's Next? - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Simply Wall St
Ashford Capital Management Inc. Trims Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Quantbot Technologies LP Sells 21,601 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
28,185 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Systematic Financial Management LP - MarketBeat
How To Trade (SUPN) - Stock Traders Daily
Charles Schwab Investment Management Inc. Purchases 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Acquires 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals executive sells shares worth $788,436 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals executive sells shares worth $788,436 - Investing.com
Supernus Pharmaceuticals, Inc. Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD - Marketscreener.com
Intech Investment Management LLC Purchases 1,838 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
PDT Partners LLC Buys Shares of 37,110 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
C21 Investments Inc (CXXI-CN) QuotePress Release - The Globe and Mail
Big Rock Brewery Inc (BR-T) QuotePress Release - The Globe and Mail
Supernus Pharmaceuticals CEO to Present at Piper Sandler Healthcare Conference | SUPN Stock News - StockTitan
Loomis Sayles & Co. L P Has $47.27 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Evertz Technologies Ltd (ET-T) QuotePress Release - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Segall Bryant & Hamill LLC Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
SUPN (Supernus Pharmaceuticals) Operating Margin % : 22.67% (As of Sep. 2024) - GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) 財務データ
収益
当期純利益
現金流量
EPS
Supernus Pharmaceuticals Inc (SUPN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Dec 27 '24 |
Option Exercise |
0.00 |
52,640 |
0 |
964,812 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Dec 03 '24 |
Option Exercise |
24.77 |
21,495 |
532,361 |
22,424 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Dec 03 '24 |
Sale |
36.68 |
21,495 |
788,437 |
9,679 |
0.94%
0.08%
大文字化:
|
ボリューム (24 時間):